Skip to main content Accessibility help
×
Home

Antibiotic Cycling: Is It Ready for Prime Time?

  • Joseph F. John (a1)
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Antibiotic Cycling: Is It Ready for Prime Time?
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Antibiotic Cycling: Is It Ready for Prime Time?
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Antibiotic Cycling: Is It Ready for Prime Time?
      Available formats
      ×

Abstract

  • An abstract is not available for this content so a preview has been provided below. To view the full text please use the links above to select your preferred format.

Copyright

Corresponding author

Division of Allergy, Immunology, and Infectious Disease, 1 RWJ Place 356 MEB, Department of Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903

References

Hide All
1.Sagan, D, Margulis, L. Garden of Microbial Delights: A Practical Guide to the Subvisible World. Boston, MA: Harcourt Brace Jovanovich, Inc, Publishers; 1988:74.
2.McGowan, JE Jr.Minimizing antimicrobial resistance in hospital bacteria: can switching or cycling drugs help? Infect Control Hosp Epidemiol 1986;7:573576.
3.Wise, R, Hart, T, Cars, O, Streulens, M, Helmuth, R, Huovinen, P, et al. Antimicrobial resistance. Is a major threat to public health. BMJ 1998;317:609610.
4.Gerberding, JL, McGowan, JE Jr, Tenover, FC. Emerging nosocomial infections and antimicrobial resistance. Curr Clin Top Infect Dis 1999;19:8398.
5.Shlaes, DM, Gerding, DN, John, JF Jr, Craig, WA, Bornstein, DL, Duncan, RA, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997;18:275291.
6.John, JF Jr, Fishman, NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997;24:471485.
7.Service, RF. Antibiotics that resist resistance. Science 1995:270:724727.
8.Knowles, DJ. New strategies for antibacterial drug design. Trends Microbiol 1997;5:379383.
9.Betts, RF, Valenti, WM, Chapman, SW, Chonmaitree, T, Mowrer, G, Pincus, P, et al. Five-year surveillance of aminoglycoside usage in a university hospital. Ann Intern Med 1984;100:219222.
10.Gerding, DN. Antimicrobial cycling: lessons learned from the aminoglycoside experience. Infect Control Hosp Epidemiol 2000;21 (suppl):S12S17.
11.Gerding, DN, Larson, TA, Hughes, RA, Weiler, M, Shanholtzer, C, Peterson, LR. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother 1991;35:12841290.
12.Gerding, DN, Larson, TA. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center. Am J Med 1985;79:17.
13.Archibald, L, Phillips, L, Monnet, D, McGowan, JE Jr, Tenover, F, Gaynes, R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211215.
14.Fridkin, SK, Edwards, JR, Pichette, SC, Pryor, ER, McGowan, JE Jr, Tenover, FC, et al. Determinants of vancomycin use in adult intensive care units in 41 Unites States hospitals. Clin Infect Dis 1999;28:11191125.
15.Hiramatsu, K, Aritaka, N, Hanaki, H, Kawasaki, S, Hosada, Y, Hori, S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:16701673.
16.Lavin, BS. Antibiotic cycling and marketing into the 21st century: a perspective from the pharmaceutical industry. Infect Control Hosp Epidemiol 2000;21 (suppl) :S32S35.
17.Kollef, MH, Vlasnik, J, Sharpless, L, Pasque C, Murphy, D, Fraser, V. Scheduled change of antibiotic classes. A strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156(4 pt 1):10401048.
18.Landman, D, Chockalingam, M, Quale, JM. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in hospital antibiotic formulary. Clin Infect Dis 1998;28:10621066.
19.Bradley, SJ, Wilson, ALT, Allen, MC, Sher, HA, Goldstone, AH, Scott, GM. The control of hyperendemic glycopeptide-resistant Enterococcus spp on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 1999;43:261266.
20.Dominguez, EA, Smith, TL, Reed, E, Sanders, CC, Sanders, WE Jr. A pilot study of antibiotic cycling in a hematology-oncology unit. Infect Control Hosp Epidemiol 2000;21(suppl):S4S8.
21.Hyatt, JM, Schentag, JJ. Potential role of pharmacokinetics, pharmacodynamics, and computerized databases in controlling bacterial resistance. Infect Control Hosp Epidemiol 2000;21(suppl):S18S21.
22.Arbeit, RD. Laboratory procedures for the epidemiologic analysis of microorganisms. In: Murray, PR, Baron, EJ, Pfaller, MA, Tenover, FC, Yolken, RH, eds. Manual of Clinical Microbiology. Washington, DC: American Society for Microbiology Press; 1999:125137.
23.Bonhoeffer, S, Lipsitch, M, Levin, BR. Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci U S A 1997;94:1210612111.
24.McGowan, JE Jr.Strategies for study of the role of cycling on antimicrobial use and resistance. Infect Control Hosp Epidemiol 2000;21 (suppl):S36S43.
25.John, JF Jr, Rice, LB. The microbial genetics of antibiotic cycling. Infect Control Hosp Epidemiol 2000;21(suppl):S22S31.
26.Hall, RM, Collis, CM. Antibiotic resistance in gram-negative bacteria: the role of gene cassettes and integrons. Drug Resistance Updates 1999;1:109119.

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed